Pathogenesis of Pulmonary Diseases
COPD is a slowly progressive condition characterized by airflow limitation, which is largely irreversible. It is characterized and defined by limitation of expiratory airflow. The current scenario is chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. The inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung injury. Pathogenesis of COPD-an imbalance between proteases and antiproteases and an imbalance between oxidants and oxidative stress in the lungs. The pathological process of chronic lung disease is based on the concept that pulmonary diseases involve stages of commencement by pollutants, infectious agents and exposure to smoke, consolidation and progression. Tissue damage involves complex interactions among oxidative stress, chronic inflammation, extracellular matrix proteolysis, and apoptotic and autophagic cell death.
- Apoptosis
- Hyperinflation
- Inflammation
- Vasoconstriction
- Emphysema
Related Conference of Pathogenesis of Pulmonary Diseases
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Pathogenesis of Pulmonary Diseases Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)